Jack Stover
About Jack Stover
Jack E. Stover is Chief Executive Officer of NorthView Acquisition Corp. (NVAC) and a member of its board; he signed recent proxy statements as CEO in 2023–2025 . He has a BA in Accounting from Lehigh University and is a Certified Public Accountant, with prior roles as CEO/President of multiple public life sciences companies and earlier as a partner at Coopers & Lybrand (PwC) . As of a 2021 public-company biography, he was age 68 and had been serving as a director at Onconova Therapeutics since 2016; since March 2021 he has served as CEO of NVAC .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Interpace Diagnostics/Biosciences, Inc. | Interim President & CEO (Dec 2015–Jun 2016); President, CEO & Director (Jun 2016–Dec 2020) | 2015–2020 | Previously audit committee chair at Interpace (2005–2015) |
| Antares Pharma, Inc. | CEO, President & Director | 2004–2008 | Public specialty pharma leadership |
| Viatar CTC Solutions, Inc. | Director; Audit Committee Chair | 2016 | Board/audit committee service |
| Coopers & Lybrand (PwC) | Partner, Bioscience industry division | Prior to 2004 | Financial reporting and audit leadership |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Onconova Therapeutics (ONTX) | Director | 2016–present (disclosed in public filings through 2022) | Audit Committee Chair; member of Compensation and Nominating/Governance at various times |
Board Governance
- Role at NVAC: Chief Executive Officer and director (signed proxies as CEO). As an executive officer, he is not characterized as an “independent” director in NVAC filings; independence status is not expressly stated in the special-meeting proxies .
- Committee assignments at NVAC: Not disclosed in the 2023–2025 special-meeting proxy statements (which were limited to extension and trust amendments) .
- Years of service on NVAC board/management: Serving as CEO since March 2021 per public-company biography; NVAC proxies confirm CEO role in 2023–2025 .
- Meeting attendance and executive sessions: Not disclosed in the available NVAC proxies .
Fixed Compensation
- NVAC disclosed: “none of our officers or directors has received any cash compensation for services rendered to the Company.” This statement appears in 2023, 2024, and 2025 proxy statements .
| Component | 2023 | 2024 | 2025 |
|---|---|---|---|
| Annual Board/Director Cash Retainer | No cash compensation disclosed | No cash compensation disclosed | No cash compensation disclosed |
| Committee Fees/Chair Fees | Not disclosed | Not disclosed | Not disclosed |
| Meeting Fees | Not disclosed | Not disclosed | Not disclosed |
Performance Compensation
- NVAC has not disclosed equity award grants (e.g., RSUs/PSUs/options) or any performance-metric framework for directors/officers in the 2023–2025 proxies; disclosures focus on SPAC extension proposals and trust amendments .
- Monthly extension contributions are structured as sponsor loans repayable only upon consummation of a business combination (a structural incentive linked to closing, not to operating performance) .
Other Directorships & Interlocks
| Company | Public/Private | Role | Committee Roles |
|---|---|---|---|
| Onconova Therapeutics (ONTX) | Public | Director | Audit Chair; service on Compensation and Nominating/Governance over time |
| Interpace Diagnostics/Biosciences | Public | Director; CEO/President (historic) | Audit Chair (historical) |
| Antares Pharma | Public | CEO/President/Director (historic) | N/A (executive) |
| Viatar CTC Solutions | Public (at the time) | Director; Audit Chair | Audit Chair |
Expertise & Qualifications
- Financial and audit expertise (CPA; former Big Four partner; multiple audit committee chair roles). This qualifies him as an audit/financial expert for governance contexts .
- Deep life sciences executive background (CEO of Interpace and Antares; operating and finance leadership) .
- SPAC governance and transactional experience as CEO of NVAC since March 2021 .
Equity Ownership
NVAC beneficial ownership (founder shares held via sponsor structure):
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Shares Beneficially Owned | 4,743,750 | 4,743,750 | 4,743,750 |
| % of Outstanding Common Stock | 76.9% | 78.7% | 80.7% |
| Notes | Interests consist solely of founder shares; held by NorthView Sponsor I, LLC; Stover is a manager and disclaims beneficial ownership except to extent of pecuniary interest |
Additional ownership structure and incentives:
- Founder shares (4,743,750) and representative shares (450,000) are not redeemable and would expire worthless if no business combination occurs, creating a strong incentive to close a deal .
- Insiders and representatives collectively controlled ~88.3% of issued and outstanding shares as of the Feb 21, 2025 record date (sponsor, officers, directors, and representatives) .
Governance Assessment
Strengths
- Extensive financial oversight credentials (CPA; repeated audit chair roles), supporting board risk oversight and internal control sophistication .
- Experienced public-company operator in life sciences; relevant to assessing targets and post-merger integration .
Risks and potential conflicts (RED FLAGS)
- Not independent at NVAC: he serves as CEO; independence is not claimed in filings, and he signed proxies as Chief Executive Officer .
- Founder-share conflict: Founder/representative shares become worthless if no business combination; officers/directors received no cash comp, heightening reliance on deal completion for value realization .
- Extension-loan structure: Monthly extension contributions are loans repayable only upon closing, reinforcing incentives to consummate a transaction even under adverse conditions .
- Concentrated control: Insiders and representatives collectively held ~88.3% of common stock as of Feb 21, 2025, limiting public shareholder influence .
- Listing and compliance risk: NVAC was delisted from Nasdaq on Dec 27, 2024 and trades on OTC Pink; delisting may hinder transaction prospects and raise investor-protection concerns .
- Process and trust-compliance concerns: Disclosed late extension payments to the trust and acknowledgment that late payments could contradict governing documents; company contributed additional amounts to offset unearned interest and noted potential for shareholder disputes if violations occurred .
Related-party exposure indicators
- Sponsor indemnity and trust protections: Sponsor agreed to indemnify if trust falls below specified thresholds under certain conditions; nonetheless, sponsor’s ability to satisfy obligations is not assured .
- No explicit related-party transactions beyond standard SPAC sponsor arrangements and extension loans are disclosed in these proxies .
Operational and shareholder process notes
- Repeated special meetings to extend trust deadlines for the Profusa business combination (Dec 2023; Sep 2024; Mar 2025), with redemption rights offered each time .
Overall implication: Stover brings strong financial and board credentials, but governance risk is elevated by his dual CEO/director role (non-independence), heavy founder-share alignment with deal completion, concentrated insider control, delisting to OTC Pink, and trust/extension process issues. Investors should weigh the quality of any proposed business combination and post-merger listing viability carefully in light of these incentives and constraints .